A single-shot coronavirus vaccine has entered the final stages of testing.
Johnson & Johnson says it's beginning a 60,000-person clinical trial on three continents. Participants will receive a single vaccine dose or a placebo.
It's made with slightly different technology than others in late-stage testing. Johnson & Johnson modeled the shot after an Ebola vaccine it created.
The vaccine could be available for emergency-use authorization in early 2021.
This makes it the fourth potential COVID-19 vaccine shot to enter late-stage testing in the U.S. Unlike the other three, it requires only one shot, not two.
